Do you want to read an article? Please log in or register.
Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment
Cardiovascular Risk and Diseases
Related content
COMMENTED
Lipid-Lowering Drugs
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants
Am Heart J.
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA
doi: 10.1016/j.ahj.2018.12.007.
Heart Failure
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure
J Am Coll Cardiol.
Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JGF, Damman K, Redon J, Coats AJS, Beta-Blockers in Heart Failure Collaborative Group.
doi: 10.1016/j.jacc.2019.09.059.
Hypertension
Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Hypertension.
Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A, Patel A, Neal B, Peiris D, Thakkar J, Chalmers J, Nelson M, Reid C, Hillis GS, Woodward M, Hilmer S, Usherwood T, Thom S, Rodgers A
doi: 10.1161/
Cardiovascular Risk and Diseases
Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction-A Systematic Review and Meta-analysis of Randomized Trials
CJC Open
Kofler T, Hess S, Moccetti F, Pepine CJ, Attinger A, Wolfrum M, Toggweiler S, Kobza R, Cuculi F, Bossard M
doi: 10.1016/j.cjco.2020.09.005
Cardiovascular Risk and Diseases
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review
JAMA.
Smilowitz NR, Berger JS
doi: 10.1001/jama.2020.7840.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesThrombosis and Stroke
Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis
BMJ.
Chowdhury R, Ramond A, O'Keeffe LM, Shahzad S, Kunutsor SK, Muka T, Gregson J, Willeit P, Warnakula S, Khan H, Chowdhury S, Gobin R, Franco OH, Di Angelantonio E
doi: 10.1136/bmj.k3310.
COMMENTED
Cardiovascular Risk and Diseases
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetologia
Lin DS, Lee JK, Hung CS, Chen WJ
doi: 10.1007/s00125-021-05529-w
Atrial FibrillationHeart Failure
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
Eur Heart J.
Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D
doi: 10.1093/
Heart, Artery and Coronary Diseases
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
Eur Heart J
Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, Thompson PL, Budgeon C, Tijssen JGP, Cornel JH
doi: 10.1093/eurheartj/ehab115